Truist Financial Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines (NASDAQ:ONC) had its target price increased by analysts at Truist Financial from $400.00 to $412.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target indicates a potential upside of 29.97% from the company’s previous close.

ONC has been the subject of several other research reports. Jefferies Financial Group restated a “buy” rating and set a $420.00 price target on shares of BeOne Medicines in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Royal Bank Of Canada raised their target price on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday. Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a report on Monday, January 12th. Finally, Citizens Jmp increased their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.25.

BeOne Medicines Trading Down 1.7%

NASDAQ ONC opened at $316.99 on Friday. The firm’s fifty day moving average is $336.81 and its two-hundred day moving average is $330.70. BeOne Medicines has a one year low of $196.45 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The firm has a market cap of $34.76 billion, a PE ratio of 125.79 and a beta of 0.52.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. Analysts expect that BeOne Medicines will post -5.82 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO John Oyler sold 24,369 shares of BeOne Medicines stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $302.87, for a total transaction of $7,380,639.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 102,656 shares of company stock valued at $31,567,496. Insiders own 6.62% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently bought and sold shares of the stock. EFG International AG purchased a new stake in shares of BeOne Medicines in the fourth quarter valued at $25,000. Anchor Investment Management LLC purchased a new stake in BeOne Medicines during the 2nd quarter worth about $26,000. Leonteq Securities AG acquired a new position in BeOne Medicines in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines in the 2nd quarter valued at about $35,000. Finally, CWM LLC boosted its stake in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.